PL369867A1 - Bicykliczne pochodne oksopirydyny i oksopirymidyny - Google Patents

Bicykliczne pochodne oksopirydyny i oksopirymidyny

Info

Publication number: PL369867A1
Authority: PL; Poland
Prior art keywords: oxopyridine; bicyclic; oxopyrimidine; derivatives; oxopyrimidine derivatives
Prior art date: 2001-10-16

Application number

PL02369867A

Other languages

English (en)

Inventor

Jeremy Martin Davis

Daniel Christopher Brookings

Barry John Langham

Original Assignee

Celltech R & D Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-16

Filing date

2002-10-16

Publication date

2005-05-02

2002-10-16 Application filed by Celltech R & D Limited filed Critical Celltech R & D Limited

2005-05-02 Publication of PL369867A1 publication Critical patent/PL369867A1/pl

Links

125000002619 bicyclic group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Virology (AREA)
Neurology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)

PL02369867A 2001-10-16 2002-10-16 Bicykliczne pochodne oksopirydyny i oksopirymidyny PL369867A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0124848.3A GB0124848D0 (en)	2001-10-16	2001-10-16	Chemical compounds

Publications (1)

Publication Number	Publication Date
PL369867A1 true PL369867A1 (pl)	2005-05-02

Family

ID=9923964

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02369867A PL369867A1 (pl)	2001-10-16	2002-10-16	Bicykliczne pochodne oksopirydyny i oksopirymidyny

Country Status (17)

Country	Link
US (1)	US7176215B2 (pl)
EP (1)	EP1438313A1 (pl)
JP (1)	JP2005505627A (pl)
KR (1)	KR20040062565A (pl)
CN (1)	CN1310921C (pl)
AU (1)	AU2002336172B2 (pl)
CA (1)	CA2462147A1 (pl)
EA (1)	EA007957B1 (pl)
GB (1)	GB0124848D0 (pl)
HU (1)	HUP0401718A3 (pl)
IL (1)	IL161384A0 (pl)
MX (1)	MXPA04003450A (pl)
NO (1)	NO20041975L (pl)
NZ (1)	NZ532713A (pl)
PL (1)	PL369867A1 (pl)
WO (1)	WO2003033502A1 (pl)
ZA (1)	ZA200402803B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
CN100369898C (zh) *	2002-02-12	2008-02-20	史密丝克莱恩比彻姆公司	用作p38抑制剂的烟酰胺衍生物
GB0214268D0 (en) *	2002-06-20	2002-07-31	Celltech R&D Ltd	Chemical compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
GB0218800D0 (en) *	2002-08-13	2002-09-18	Celltech R&D Ltd	Chemical compounds
GB0222743D0 (en) *	2002-10-01	2002-11-06	Celltech R&D Ltd	Chemical compounds
UA81453C2 (en) *	2003-02-27	2008-01-10		Pyrazolopyridine derivates
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
CA2526285A1 (en)	2003-05-15	2004-12-23	Arqule, Inc.	Inhibitors of p38 and methods of using the same
US7119205B2 (en) *	2003-05-16	2006-10-10	Abbott Laboratories	Thienopyridones as AMPK activators for the treatment of diabetes and obesity
DE602004017609D1 (de) *	2003-06-20	2008-12-18	Ucb Pharma Sa	Verfahren zur herstellung von 3-aminothienopyridon-derivaten
AU2004249495A1 (en)	2003-06-20	2004-12-29	Ucb Pharma S.A.	Thienopyridone derivatives as kinase inhibitors
CA2528603A1 (en) *	2003-06-20	2004-12-29	Celltech R & D Limited	Thienopyridone derivatives as kinase inhibitors
WO2005042540A1 (en) *	2003-10-24	2005-05-12	Celltech R & D Limited	Thieno-pyridinone derivatives as kinase inhibitors
JP2007517052A (ja) *	2003-12-23	2007-06-28	ノバルティスアクチエンゲゼルシャフト	二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
GB0402138D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402140D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402137D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
WO2006010082A1 (en)	2004-07-08	2006-01-26	Arqule, Inc.	1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en)	2004-10-19	2006-04-27	Arqule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
ATE476434T1 (de) *	2004-12-09	2010-08-15	Xention Ltd	Thienopyridinderivate als kaliumkanalinhibitoren
AP2007004244A0 (en)	2005-05-10	2007-12-31	Intermune Inc	Method of modulating stress-activated protein kinase system
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
US20110034495A1 (en) *	2005-11-23	2011-02-10	Intermune, Inc.	Method of Modulating Stress-Activated Protein Kinase System
JP2009520015A (ja) *	2005-12-20	2009-05-21	リヒターゲデオンニュルト	新規な化合物
HUP0501168A3 (en) *	2005-12-20	2007-10-29	Richter Gedeon Nyrt	2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
AU2008340422B2 (en) *	2007-12-21	2014-06-19	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2296653B1 (en) *	2008-06-03	2016-01-27	Intermune, Inc.	Compounds and methods for treating inflammatory and fibrotic disorders
GB0915892D0 (en) *	2009-09-10	2009-10-14	Smithkline Beecham Corp	Compounds
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
US9056099B2 (en)	2010-03-01	2015-06-16	Novadrug, Llc	Compositions and methods for treating viral diseases
CA2846348C (en)	2011-08-24	2019-01-22	Novadrug, Llc	Compositions comprising perhydropyrrolo[3,2-c]pyridines and methods for their use in treating viral diseases
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
RU2692485C2 (ru)	2014-04-02	2019-06-25	Интермьюн, Инк.	Противофиброзные пиридиноны
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10906899B2 (en)	2016-05-10	2021-02-02	Georgia State University Research Foundation, Inc.	Bicyclic fused pyrazole derivatives for the treatment of RSV
CN116925045B (zh) *	2020-12-15	2026-05-01	中国科学院上海药物研究所	甲状腺素受体β选择性激动剂化合物、其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR77945B (pl) *	1982-03-30	1984-09-25	Lepetit Spa
US5219864A (en) *	1991-03-12	1993-06-15	Kyowa Hakko Kogyo Co., Ltd.	Thienopyridine derivatives
CA2121148A1 (en) *	1992-08-19	1994-03-03	Otsuka Pharmaceutical Co., Ltd.	Apoptosis regulator
JPH0776586A (ja) *	1993-07-16	1995-03-20	Yoshitomi Pharmaceut Ind Ltd	ピリジン化合物
DE4444815A1 (de) *	1994-12-15	1996-06-20	Merck Patent Gmbh	Thienopyridone
JPH0959276A (ja) *	1995-08-11	1997-03-04	Kumiai Chem Ind Co Ltd	縮合ヘテロ環誘導体及び除草剤
AU4429799A (en) *	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
GB2350111A (en) *	1999-05-17	2000-11-22	Bayer Ag	Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
AU778042B2 (en) *	1999-10-19	2004-11-11	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2001037837A1 (en)	1999-11-23	2001-05-31	Smithkline Beecham Corporation	3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
AR030053A1 (es)	2000-03-02	2003-08-13	Smithkline Beecham Corp	1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
AR030273A1 (es) *	2000-03-10	2003-08-20	Smithkline Beecham Corp	Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina

2001
- 2001-10-16 GB GBGB0124848.3A patent/GB0124848D0/en not_active Ceased
2002
- 2002-10-16 JP JP2003536241A patent/JP2005505627A/ja not_active Abandoned
- 2002-10-16 CN CNB02825094XA patent/CN1310921C/zh not_active Expired - Fee Related
- 2002-10-16 EP EP02770072A patent/EP1438313A1/en not_active Withdrawn
- 2002-10-16 HU HU0401718A patent/HUP0401718A3/hu unknown
- 2002-10-16 KR KR10-2004-7005544A patent/KR20040062565A/ko not_active Ceased
- 2002-10-16 MX MXPA04003450A patent/MXPA04003450A/es not_active Application Discontinuation
- 2002-10-16 EA EA200400550A patent/EA007957B1/ru not_active IP Right Cessation
- 2002-10-16 WO PCT/GB2002/004680 patent/WO2003033502A1/en not_active Ceased
- 2002-10-16 PL PL02369867A patent/PL369867A1/pl not_active Application Discontinuation
- 2002-10-16 NZ NZ532713A patent/NZ532713A/en unknown
- 2002-10-16 US US10/492,466 patent/US7176215B2/en not_active Expired - Fee Related
- 2002-10-16 IL IL16138402A patent/IL161384A0/xx unknown
- 2002-10-16 CA CA002462147A patent/CA2462147A1/en not_active Abandoned
- 2002-10-16 AU AU2002336172A patent/AU2002336172B2/en not_active Ceased
2004
- 2004-04-13 ZA ZA200402803A patent/ZA200402803B/en unknown
- 2004-05-13 NO NO20041975A patent/NO20041975L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20041975L (no)	2005-07-16
US7176215B2 (en)	2007-02-13
MXPA04003450A (es)	2004-07-16
EA200400550A1 (ru)	2004-10-28
HUP0401718A2 (hu)	2004-12-28
HUP0401718A3 (en)	2008-07-28
ZA200402803B (en)	2006-06-28
US20040254200A1 (en)	2004-12-16
EA007957B1 (ru)	2007-02-27
JP2005505627A (ja)	2005-02-24
KR20040062565A (ko)	2004-07-07
NO20041975D0 (no)	2004-05-13
NZ532713A (en)	2005-10-28
EP1438313A1 (en)	2004-07-21
CA2462147A1 (en)	2003-04-24
IL161384A0 (en)	2004-09-27
GB0124848D0 (en)	2001-12-05
WO2003033502A1 (en)	2003-04-24
AU2002336172B2 (en)	2007-09-13
CN1604901A (zh)	2005-04-06
CN1310921C (zh)	2007-04-18

Legal Events

Date	Code	Title	Description
2010-11-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL161384A0 (en)	2004-09-27	Bicyclic oxopyridine and oxopyrimidine derivatives
EG24356A (en)	2009-03-04	Antitumor compounds and methods
PT1438306E (pt)	2014-06-03	Derivados de uk-20
AU2002352903A8 (en)	2003-06-10	Mesoporous materials and methods
EP1423120A4 (en)	2005-12-28	2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
IL160701A0 (en)	2004-08-31	3-substituted-4-pyrimidone derivatives
AU2002352221A1 (en)	2003-06-30	Bicyclic n-arylamides
IL163868A0 (en)	2005-12-18	Hermiasterlin derivatives and uses thereof
PL369510A1 (pl)	2005-04-18	Spirocykliczne 3-fenylo-3-podstawione 4-ketolaktamy i 4-ketolaktony
EP1434772A4 (en)	2005-05-04	CONNECTIONS AND METHODS
GB0104206D0 (en)	2001-04-11	Radiometers
IL154553A0 (en)	2003-09-17	Urocortin-iii and uses thereof
HUP0401949A3 (en)	2009-07-28	4-imidazolin-2-one derivatives
HUP0303186A3 (en)	2007-06-28	4-aminobenzopyran derivatives
HUP0500026A3 (en)	2008-02-28	N-heteroarylnicotinamide derivatives
EP1392317A4 (en)	2005-10-19	SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
GB0126889D0 (en)	2002-01-02	Compounds and their uses
AU2002359694A8 (en)	2003-06-30	Compounds and methods
HUP0500734A3 (en)	2005-12-28	Use of 2-alkoxyphenyl-substituted imidazotriazinones
AU2003297612A8 (en)	2004-06-23	2-substituted-3-propenamide derivatives and methods of using the same
EP1404670A4 (en)	2004-11-24	SEMICARBAZIDES AND THEIR USE
HUP0401162A3 (en)	2007-05-02	Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
IL158001A0 (en)	2004-03-28	Bicyclic guanidine derivatives and therapeutic uses thereof
GB2384041B (en)	2004-07-07	Combination fitting
EP1364954A4 (en)	2009-10-28	Dicarba closo DODECARBORANDERIVATE